Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens

The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinetti, Antonia, Miceli, Rosalba, Sottotetti, Elisa, Di Bartolomeo, Maria, de Braud, Filippo, Gevorgyan, Arpine, Dotti, Katia Fiorella, Bajetta, Emilio, Campiglio, Manuela, Bianchi, Francesca, Bregni, Giacomo, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190566/
https://www.ncbi.nlm.nih.gov/pubmed/25256831
http://dx.doi.org/10.3390/cancers6031753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190566/
https://www.ncbi.nlm.nih.gov/pubmed/25256831
http://dx.doi.org/10.3390/cancers6031753

Ejemplares similares